- Home
- ENTX vs HOWL Comparison
ENTX vs HOWL Comparison
Compare ENTX & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- HOWL
- Stock Information
- Founded
- ENTX 2010
- HOWL 2017
- Country
- ENTX Israel
- HOWL United States
- Employees
- ENTX N/A
- HOWL N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- ENTX Health Care
- HOWL Health Care
- Exchange
- ENTX Nasdaq
- HOWL Nasdaq
- Market Cap
- ENTX 82.2M
- HOWL 64.5M
- IPO Year
- ENTX 2018
- HOWL 2021
- Fundamental
- Price
- ENTX $1.80
- HOWL $1.45
- Analyst Decision
- ENTX Strong Buy
- HOWL Strong Buy
- Analyst Count
- ENTX 1
- HOWL 5
- Target Price
- ENTX $10.00
- HOWL $7.20
- AVG Volume (30 Days)
- ENTX 79.6K
- HOWL 177.7K
- Earning Date
- ENTX 11-07-2025
- HOWL 11-06-2025
- Dividend Yield
- ENTX N/A
- HOWL N/A
- EPS Growth
- ENTX N/A
- HOWL N/A
- EPS
- ENTX N/A
- HOWL N/A
- Revenue
- ENTX $166,000.00
- HOWL N/A
- Revenue This Year
- ENTX N/A
- HOWL N/A
- Revenue Next Year
- ENTX N/A
- HOWL N/A
- P/E Ratio
- ENTX N/A
- HOWL N/A
- Revenue Growth
- ENTX 191.23
- HOWL N/A
- 52 Week Low
- ENTX $1.50
- HOWL $0.60
- 52 Week High
- ENTX $2.79
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- ENTX 41.03
- HOWL 61.06
- Support Level
- ENTX $1.77
- HOWL $1.38
- Resistance Level
- ENTX $1.89
- HOWL $1.49
- Average True Range (ATR)
- ENTX 0.11
- HOWL 0.07
- MACD
- ENTX -0.02
- HOWL 0.01
- Stochastic Oscillator
- ENTX 6.67
- HOWL 72.73
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.